Similar to the PBMCs of healthy volunteers, both the CD14+ and CD56+ immune effector cells in the PBMCs of breast cancer patients’ showed HER2-trogocytosis (Figure 3A) and target cell cytotoxicity (Figure 3B). Here, CD14 is linked to breast carcinoma.